- Conditions
- Post Surgical Ocular Inflammation and Pain
- Interventions
- KPI-121 1% Ophthalmic Suspension dosed BID, Vehicle of KPI-121 Ophthalmic Suspension dosed BID
- Drug
- Lead sponsor
- Kala Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 35
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Artesia, California + 32 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1033–1056
of 2,374
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Vision Loss
- Interventions
- Not listed
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 7 Years to 50 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- brimonidine 0.1%, Apraclonidine 0.5%
- Drug
- Lead sponsor
- Walter Reed Army Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Glaucoma, Open-Angle, Cataract
- Interventions
- Vivity IOL
- Device
- Lead sponsor
- Vold Vision P.L.L.C
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Fayetteville, Arkansas
- Conditions
- Sessile Serrated Adenoma
- Interventions
- Endocuff Vision Assisted Colonoscopy
- Device
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 427 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Obesity, Behavior, Health, Weight Loss
- Interventions
- Noom Healthy Weight; mobile behavior change program for weight loss., Matched Control
- Behavioral · Other
- Lead sponsor
- Noom Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Commack, New York
- Conditions
- Glaucoma, Open-Angle, Glaucoma; Drugs
- Interventions
- dorzolamide/timolol
- Drug
- Lead sponsor
- CT Glaucoma Associates
- Other
- Eligibility
- 25 Years to 90 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Norwalk, Connecticut
- Conditions
- Glaucoma and Ocular Hypertension
- Interventions
- Low Energy SLT, Standard Energy SLT
- Procedure
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 790 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 28
- States / cities
- Laguna Hills, California • Pasadena, California • Sacramento, California + 22 more
- Conditions
- Cataract
- Interventions
- AcrySof ReSTOR Aspheric IOL model SN6AD1
- Device
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Perception of Things Changing Color, Adaptive Behavior
- Interventions
- Mode Switching Training
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Glaucoma
- Interventions
- Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, placebo eye drops
- Drug · Procedure · Other
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Dothan, Alabama
- Conditions
- Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
- Interventions
- NIO752, Placebo
- Other · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 41 Years to 81 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • San Francisco, California • Englewood, Colorado + 6 more
- Conditions
- Migraine Headaches
- Interventions
- ELS-M11, Placebo
- Drug
- Lead sponsor
- Achelios Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Charleston, South Carolina
- Conditions
- Retinopathy of Prematurity
- Interventions
- Bevacizumab, Conventional Laser for ROP
- Drug · Procedure
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 4 Weeks to 22 Weeks
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 15
- States / cities
- Pasadena, California • Denver, Colorado • Peoria, Illinois + 7 more
- Conditions
- Forehead; Wound
- Interventions
- Group 1 cannabidiol (CBD) with silicone ointment, Group 2 silicone patch
- Biological
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Healthy
- Interventions
- Loteprednol Etabonate
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Inglewood, California
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- BOL-303259-X, Timolol
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Keratoconjunctivitis Sicca
- Interventions
- Retaine™
- Drug
- Lead sponsor
- Ocusoft, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Macular Degeneration
- Interventions
- intravitreal injection Lucentis (ranibizumab)
- Drug
- Lead sponsor
- Retina Research Foundation
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Slingerlands, New York
- Conditions
- Open-Angle Glaucoma
- Interventions
- Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis
- Procedure
- Lead sponsor
- Barnet Dulaney Perkins Eye Centers
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Mesa, Arizona
- Conditions
- Graft Versus Host Disease, Ocular Surface Disease, oGVHD, Ocular Graft vs Host Disease, Brimonidine Tartrate, Lubricant Eye Drops, Ophthalmic Solutions, Graft vs Host Disease
- Interventions
- Brimonidine Tartrate, Placebos
- Drug
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 10 more
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Albinism, Vision Loss
- Interventions
- Nitisinone
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Uveal Melanoma
- Interventions
- Melphalan through Percutaneous Hepatic Perfusion
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts